US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

STTK

Shattuck Labs (STTK)

Shattuck Labs Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:STTK

1 2 3 4 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
14/05/2024	15:15	GlobeNewswire Inc.	Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the Eu	NASDAQ:STTK	Shattuck Labs Inc
14/05/2024	15:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:STTK	Shattuck Labs Inc
02/05/2024	06:05	GlobeNewswire Inc.	Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights	NASDAQ:STTK	Shattuck Labs Inc
09/04/2024	15:05	GlobeNewswire Inc.	Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024	NASDAQ:STTK	Shattuck Labs Inc
01/04/2024	06:00	GlobeNewswire Inc.	Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:STTK	Shattuck Labs Inc
08/03/2024	16:29	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:STTK	Shattuck Labs Inc
06/03/2024	15:42	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:STTK	Shattuck Labs Inc
04/03/2024	06:14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:STTK	Shattuck Labs Inc
04/03/2024	06:00	GlobeNewswire Inc.	Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors	NASDAQ:STTK	Shattuck Labs Inc
29/02/2024	15:41	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:STTK	Shattuck Labs Inc
29/02/2024	15:23	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:STTK	Shattuck Labs Inc
29/02/2024	15:05	GlobeNewswire Inc.	Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights	NASDAQ:STTK	Shattuck Labs Inc
26/02/2024	06:00	GlobeNewswire Inc.	Shattuck Labs Announces Participation in Upcoming March Conferences	NASDAQ:STTK	Shattuck Labs Inc
14/02/2024	04:06	PR Newswire (US)	Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins	NASDAQ:STTK	Shattuck Labs Inc
13/02/2024	05:00	GlobeNewswire Inc.	Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases	NASDAQ:STTK	Shattuck Labs Inc
02/02/2024	15:32	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:STTK	Shattuck Labs Inc
31/01/2024	23:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:STTK	Shattuck Labs Inc
24/01/2024	15:31	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:STTK	Shattuck Labs Inc
08/01/2024	06:00	GlobeNewswire Inc.	Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2024	NASDAQ:STTK	Shattuck Labs Inc
04/01/2024	15:05	GlobeNewswire Inc.	Shattuck Labs Announces Presentation at Upcoming 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:STTK	Shattuck Labs Inc
22/12/2023	15:00	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:STTK	Shattuck Labs Inc
21/12/2023	07:00	GlobeNewswire Inc.	Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants	NASDAQ:STTK	Shattuck Labs Inc
13/12/2023	08:00	AllPennyStocks.com	Small Cap Steals The Show With Wild Premarket Action	NASDAQ:STTK	Shattuck Labs Inc
13/12/2023	05:00	GlobeNewswire Inc.	Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Pati	NASDAQ:STTK	Shattuck Labs Inc
05/12/2023	15:15	GlobeNewswire Inc.	Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation Dat	NASDAQ:STTK	Shattuck Labs Inc
14/11/2023	08:00	GlobeNewswire Inc.	Shattuck Labs Announces Participation in Upcoming 6th Annual Evercore ISI HealthCONx Conference	NASDAQ:STTK	Shattuck Labs Inc
09/11/2023	06:03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:STTK	Shattuck Labs Inc
09/11/2023	05:00	GlobeNewswire Inc.	Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights	NASDAQ:STTK	Shattuck Labs Inc
06/11/2023	08:28	GlobeNewswire Inc.	Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023	NASDAQ:STTK	Shattuck Labs Inc
02/11/2023	08:01	GlobeNewswire Inc.	Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 Annual	NASDAQ:STTK	Shattuck Labs Inc

Showing the most relevant articles for your search:NASDAQ:STTK

1 2 3 4 Próxima >

Old National Bancorp

Fundo DE Investimento Im...

Trilogy International Pa...

Bluestar Secutech

Full Alliance (PK)

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones